Molina Healthcare, Inc. (NYSE:MOH) is one of the 15 Best Stocks to Buy According to Billionaire Seth Klarman. Molina Healthcare, Inc. (NYSE:MOH) is a new addition to the 13F portfolio of Baupost Group. This holding comprises more than 620,000 shares. In early February, the company had released earnings for the fourth quarter of 2025, with the management projecting 2026 premium revenue of approximately $42 billion. This is slightly lower than 2025. The management expects Medicaid 2026 rates to average appr ...

Seth Klarman of Baupost Group manages a 13F portfolio worth more than $5.2 billion at the end of the fourth quarter of 2025. The top holdings in his equity portfolio are concentrated in the consumer cyclical, technology, and industrial sectors.In May 2025, Klarman sat down for a conversation with Goldman Sachs President and COO John Waldron, discussing the ways in which his value-oriented investment philosophy was playing out in the stock market. During the talk, Klarman underlined the basic margin of safet ...

ANN ARBOR, Mich.--(BUSINESS WIRE)--Molina Healthcare of Michigan and The MolinaCares Accord Donate $135,000 to senior centers to pilot programs addressing social isolation. ...

Long Beach, California-based Molina Healthcare, Inc. (MOH) provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces in the United States. The company has a market capitalization of $7.5 billion and operates through Medicaid, Medicare, Marketplace, and Other segments. Companies with a market cap between $2 billion and $10 billion are typically referred to as “mid-cap stocks.” Molina Healthcare sits com ...

Group 1 - Molina Healthcare, Inc. is identified as a long-term loser in the S&P 500, with significant exposure to Medicare and Medicaid, which are considered weak segments of the business [1] - The stock has declined by 63% over the past two years, indicating a substantial drop in market value [1] - The company provides managed health services for low-income individuals and families through federal and state programs, and has no exposure to tariffs, which contributed to a 4% stock rally on a specific day [2] Group 2 - The stock is down nearly 55% since the time of the previous comments, suggesting ongoing challenges for the company [3] - While there is potential for Molina Healthcare as an investment, certain AI stocks are viewed as having greater upside potential and less downside risk [3]

Core Viewpoint - Kahn Swick & Foti, LLC has initiated an investigation into Molina Healthcare, Inc. following a significant cut in the company's earnings guidance and a subsequent securities class action lawsuit against its executives [1] Financial Performance - Molina Healthcare reported a GAAP net income of $4.75 per diluted share for Q2 2025, representing an 8% decrease year-over-year [1] - The company revised its full-year 2025 adjusted earnings guidance to no less than $19.00 per diluted share, marking a 13.6% reduction from previous guidance [1] - Molina also cut its full-year 2025 GAAP net income guidance by 27% to $912 million, attributing the results to challenging medical cost trends, including increased utilization of behavioral health, pharmacy, and inpatient and outpatient services [1] Legal Issues - Following the earnings report, Molina and certain executives faced a securities class action lawsuit for allegedly failing to disclose material information during the class period, violating federal securities laws [1] - Kahn Swick & Foti's investigation is focused on whether Molina's officers and/or directors breached their fiduciary duties to shareholders or violated state or federal laws [1]

Core Viewpoint - Nvidia-related AI stocks Vertiv (VRT), Lumentum (LITE), and Coherent (COHR) will be added to the S&P 500 index on March 23, alongside Echostar (SATS), as part of the quarterly rebalancing [1] Group 1: Stock Performance - Vertiv stock increased by 5.2% in after-hours trading, despite a 5.1% decline during the week to $241.78, maintaining above its 21-day moving average [1] - Lumentum stock rose by 1.7%, while Coherent stock saw a slight increase of 0.5% [1] - Echostar stock climbed 3.2% after hours, recovering from an 8% drop to $106.24 last week [1] Group 2: Nvidia Investments - Nvidia invested $2 billion each in optical companies Lumentum and Coherent, which are partners in AI infrastructure [1] Group 3: Index Changes - The new additions to the S&P 500 will replace Match Group (MTCH), Molina Healthcare (MOH), Lamb Weston (LW), and Paycom Software (PAYC) [1] - Micron Technology (MU), Lam Research (LRCX), Applied Materials (AMAT), and GE Vernova (GEV) will join the S&P 100 index, replacing Target (TGT), Metlife (MET), PayPal (PYPL), and American International Group (AIG) [1]

Group 1 - The company reiterated its guidance of $5 per share for the full year 2026, indicating confidence in its financial outlook [1] - The CFO noted that it is too early to provide updates on cost trends and utilization, as only January data is available [1] - The company remains confident in its performance despite the early stage of the reporting period [1]

Summary of Molina Healthcare FY Conference Call Company Overview - **Company**: Molina Healthcare (NYSE: MOH) - **Date**: March 03, 2026 - **Speaker**: Mark Keim, Senior EVP and Chief Financial Officer Key Points Financial Guidance and Performance - Molina reiterated its guidance of **$5 per share** for the full year 2026, with confidence in achieving this despite current challenges [3][4] - The company anticipates a decline in Marketplace membership from **24 million** to an estimated **15 million-18 million** due to renewal payment uncertainties [5][6] - The **Medicaid Medical Loss Ratio (MLR)** is projected to be **92.9%**, higher than previously expected, impacting overall profitability [8][10] Market Dynamics - The company is experiencing a **deteriorating Medicaid MLR**, which has affected its financial outlook [8] - Molina's performance is characterized by a **400 basis points** better MLR compared to the market, indicating strong operational efficiency [14][18] - The **California retro adjustment** related to undocumented populations has uniquely impacted Molina, as it has a significant number of members in this category [12][13] Embedded Earnings and Future Opportunities - Molina identifies **$11 per share** in embedded earnings from new contracts and acquisitions not yet reflected in current earnings [16][17] - The company is focusing on high-acuity populations, particularly in Florida, where it believes it can achieve attractive margins despite initial performance challenges [24][25] Medicaid Trends and Projections - The company views **2026 as a trough year** for margins, with expectations of recovery in subsequent years as acuity shifts stabilize [27][28] - Molina anticipates a **5% trend** in 2026, down from **7.5%** in 2025, as the impact of low users exiting the system diminishes [28][29] - The market is currently underfunded by **400 basis points**, which Molina believes will necessitate rate adjustments to return to target margins [32][48] Strategic Positioning - Molina is exiting the **Medicare Advantage (MAPD)** market to focus on its core duals strategy, which aligns better with its Medicaid business [20][22] - The company is well-positioned to capitalize on the integrated duals market, leveraging its existing Medicaid footprint to enhance member experience and clinical outcomes [51][52] Regulatory Environment and State Interactions - States are becoming more receptive to discussions about benefit management and utilization management as they face budget pressures [35][37] - Molina's consistent performance across various states indicates a stable operational model, reducing the likelihood of exiting any state markets [39][40] Conclusion - Molina Healthcare is navigating a challenging environment with a focus on maintaining operational efficiency and capitalizing on embedded earnings opportunities. The company is strategically positioned to leverage its strengths in high-acuity populations and integrated care models while addressing the financial pressures within the Medicaid landscape.

Core Viewpoint - Molina Healthcare, Inc. is facing challenges due to rising costs in Medicaid and Medicare segments, leading to a significant decline in stock performance over the past year and underperformance compared to the broader market and its sector [2][3]. Company Overview - Molina Healthcare, Inc. is headquartered in Long Beach, California, and operates managed care plans for low-income families and individuals through Medicaid and Medicare programs, with a market capitalization of $7.78 billion [1]. Stock Performance - Over the past 52 weeks, Molina's stock has dropped 48.2%, and it is down 13% year-to-date (YTD). The stock reached a 52-week low of $121.06 on February 11 but has since recovered by 24.7%, gaining 19.2% over the past five days [2]. - In comparison, the S&P 500 Index has gained 13% over the past 52 weeks, indicating that Molina's stock has underperformed the broader market [3]. Financial Results - For the fourth quarter of fiscal 2025, Molina reported total revenue of $11.38 billion, an increase of 8.3% year-over-year (YOY), driven by premium revenue rising 7.3% to $10.72 billion [3]. - The company reported an adjusted loss per share of $2.75, missing analysts' consensus estimates, and a significant decline from the $5.05 EPS reported a year earlier, impacted by approximately $2.00 of unfavorable retroactive revenue items [4]. Future Expectations - For the current year, Molina expects premium revenue of about $42 billion, a decrease of 2% from 2025, and adjusted EPS of at least $5.00 on a diluted basis. Analysts predict a 54.3% YOY decrease in EPS to $5.04 for fiscal 2026, followed by a 146% improvement to $12.40 in fiscal 2027 [5]. Analyst Ratings - Among 18 Wall Street analysts covering Molina's stock, the consensus rating is a "Hold," consisting of two "Strong Buy" ratings, 13 "Holds," one "Moderate Sell," and two "Strong Sells." The ratings have become less bullish compared to a month ago, with a decrease in "Strong Buy" ratings from three to two [6][7].